All Type of News
CKD’s sales performance stands out among Big 5 pharmas
It was observed the 3rd quarter’s sales performance of Chong Kun Dang(CKD) stood out compared to the ‘Big 5’ pharmaceutical companies.
According to the analysis result of 2016’s sales performances tentatively aggrega...
Celltrion applies approval of antibody biosimilar ‘Herzuma’ to EMAOn the 27th of October(local time), Celltrion announced the application for approval of the antibody biosimilar to treat breast cancer, ‘Herzuma,’ was officially accepted at the...
|
Hanmi announces start on Phase 3 clinical trials for ‘efpeglenatide’ in 2017
On the 28th, Hanmi Pharm(CEO Kwan-Soon Lee) announced it plans to start Phase 3 clinical trials of a new antidiabetic, whose license was agreed with Sanofi last year, ‘efpeglenatide,’ in 2017.
Hanmi Pharm and Sanofi...
Korean companies might face ‘global trails’ due to late responses to ‘urgent’ Nagoya Protocol
Even in Korea, it was criticized companies should more actively response to the Nagoya Protocol; this is because they might get involved in ‘global lawsuits.’
In the ‘Has everyone been getting ready for the urgent N...
‘Self-sufficient rate’ keeps dropping as Korea’s drug competitiveness falls
It was observed the Korea’s self-sufficiency rate in finished drug is getting lower, and the self-sufficiency rate in pharmaceutical ingredient is increasing.
According to the ‘2016 Food and Drug Statistics Annual R...
How will list pharmas’ ‘sales ranking’ & ‘KRW 1 trillion club’ be?
While the industry has paid attention to the pharmaceutical companies’ final sales ranking as their 3rd quarter’s sales records are released, which pharmaceutical companies will achieve KRW 1 trillion sales are gettin...
No. of OTC drugs to keep dropping every year
The number and amount of OTC drugs manufactured are observed to decrease.
According to the Ministry of Food and Drug Safety(MFDS), it was observed the number of pharmaceutical products manufactured in 2015 was 17,907...
Hanlim wins 2nd trial for Allergan’s ‘Combigan’ composition patent, too
Hanlim Pharm, which filed the nullification trial of the glaucoma-treating ‘Combigan’ composition patent, won the 2nd trial, too, against Allergan owning the original product.
This winning has raise the chance for Ha...
Baraclude directly suffering from 53.55% price cuts
A hepatitis B treatment which had kept the No. 1 position in the prescription market for several years, ‘Baraclude’ is now experiencing sharp decreases in prescription in a year of its patent expiration.
It is true i...
‘Hidden champions,’ Japanese pharmas to target Korean market
Japanese pharmaceutical companies branched in Korea are on a roll, showing themselves as ‘hidden champions’ in the Korean industry. Although they are not as global as international companies such as Novartis and Pfize...
